Amneal Pharmaceuticals, Inc. (AMRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $13.12. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AMRX = $172.64 (+1215.9% from the current price, the stock appears undervalued). Analyst consensus target is AMRX = $16 (+22% upside).
Valuation: AMRX trades at a trailing Price-to-Earnings (P/E) of 55.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.93.
Financials: revenue is $3.0B, +11%/yr average growth. Net income is $72M, growing at +52.6%/yr. Net profit margin is 2.4% (thin). Gross margin is 37.6% (+1.8 pp trend).
Balance sheet: total debt is $2.7B with negative equity of -$71M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.17 (strong liquidity). Debt-to-assets is 74.4%. Total assets: $3.7B.
Analyst outlook: 10 / 16 analysts rate AMRX as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 54/100 (Partial), Growth 90/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 56/100 (Partial), Future 67/100 (Pass), Income 30/100 (Fail).
